Format

Send to

Choose Destination
Eur J Nucl Med Mol Imaging. 2019 Jul 22. doi: 10.1007/s00259-019-04435-z. [Epub ahead of print]

Current experts' views on precision nuclear medicine imaging of phaeochromocytoma and paraganglioma.

Author information

1
Department of Nuclear Medicine, La Timone University Hospital, CERIMED, Aix-Marseille University, 264 rue Saint-Pierre, 13005, Marseille Cedex 05, France. david.taieb@ap-hm.fr.
2
Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institutes of Child Health and Human Development, National Institutes of Health, Building 10, CRC, Room 1E-3140, 10 Center Drive MSC-1109, Bethesda, MD, 20892-1109, USA. karel@mail.nih.gov.

Abstract

The EANM/SNMMI 2019 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma (PPGL) describe the current experts' views on molecular imaging in the era of precision medicine, and contain all of the information needed by nuclear physicians for performing, interpreting, and reporting the results of imaging investigations. This editorial, from a clinician's perspective, describes the first-choice radiopharmaceutical for a particular clinical setting as an important element of the revised guidelines. It also gives new evidence-based data showing the steadily growing role of nuclear imaging in PPGL phenotyping and assessment of their clinical characteristics and outcomes.

PMID:
31332495
DOI:
10.1007/s00259-019-04435-z

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center